95798-31-5

Upstream product

• 2026-48-4 (S)-valinol 
• 24210-19-3 methyl (2S)-3-methyl-[(benzyloxy)carbonylamino]butanoate 
• 458-69-5 3-phenylpropanoic acid fluoride 
• 17016-83-0 (4S)-4-isopropyl-1,3-oxazolidin-2-one 
• 501-52-0 3-Phenylpropionic acid 
• 645-45-4 hydrocinnamic acid chloride 
• 95798-35-9 (4S)-3-<(2S)-1-oxo-2-<<(phenylmethyl)thio>methyl>-3-phenylpropyl>-4-(1-methylethyl)-2-oxazolidinone 

Downstream Products

• 95798-35-9 (4S)-3-<(2S)-1-oxo-2-<<(phenylmethyl)thio>methyl>-3-phenylpropyl>-4-(1-methylethyl)-2-oxazolidinone 
• 129779-05-1 (S)-3-((R)-2-Benzyloxymethyl-3-phenyl-propionyl)-4-isopropyl-oxazolidin-2-one 
• 161815-10-7 (2R,3S)-1,4-bis[(4S)-4-isopropyl-2-oxo(1,3-oxazolidin-3-yl)]-2,3-bisbenzylbutane-1,4-dione 
• 161745-70-6 (2R,3R)-1,4-bis[(4S)-4-isopropyl-2-oxo(1,3-oxazolidin-3-yl)]-2,3-bisbenzylbutane-1,4-dione 
• 96930-42-6 (S)-3-((S)-2-Hydroxy-3-phenyl-propionyl)-4-isopropyl-oxazolidin-2-one 
• 126401-45-4 3-<2-(R)-benzyl-3-(benzyloxycarbonyl)propionyl>-4-(S)-isopropyl-2-oxazolidinone 
• 116129-79-4 (4S)-3-<(2R)-2-<(tert-butyloxycarbonyl)methyl>-3-phenylpropionyl>-4-(2-propyl)oxazolidin-2-one 
• 1049037-32-2 C₂₄H₃₂F₃NO₅ 
• 1049037-36-6 C₃₄H₃₉NO₅ 
• 1049037-37-7 C₃₁H₃₈N₂O₅ 
• 1049037-43-5 C₂₈H₃₄FNO₅ 
• 1049037-44-6 C₂₈H₃₄FNO₅ 

Relevant academic research and scientific papers

MACROCYCLIC PICOLINAMIDES AS FUNGICIDES

This disclosure relates to macrocyclic picolinamides of Formula (I) described herein, wherein X, Y, R1 and R2 are as defined herein and to their use as fungicides in a formulation comprising a phytologically acceptable carrier. Also provided are methods of using compounds of Formula (I) in combination with other pesticides including fungicides, insecticides, nematocides, miticides, arthropodicides, bactericides, and combinations thereof.

A protocol for amide bond formation with electron deficient amines and sterically hindered substrates

A protocol for amide coupling by in situ formation of acyl fluorides and reaction with amines at elevated temperature has been developed and found to be efficient for coupling of sterically hindered substrates and electron deficient amines where standard methods failed.

COMPOUNDS CONTAINING FUSED RINGS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF

The invention provides novel beta-secretase inhibitors and methods for their use, including methods of treating Alzheimer's disease.

Deglycobleomycin A6 analogues modified in the methylvalerate moiety

Previous studies have indicated that the methylvalerate subunit of bleomycin (BLM) plays an important role in facilitating DNA cleavage by BLM and deglycoBLM. Eleven methylvalerate analogues have been synthesized and incorporated into deglycoBLM congeners by the use of solid-phase synthesis. The effect of the valerate moiety in the deglycoBLM analogues has been studied by comparison with the parent deglycoBLM A5 using supercoiled DNA relaxation and sequence-selective DNA cleavage assays. All of the deglycoBLM analogues were found to effect the relaxation of the plasmid DNA. Those analogues having aromatic C4-substituents exhibited cleavage efficiency comparable to that of deglycoBLM A5. Some, but not all, of the deglycoBLM analogues were also capable of mediating sequence-selective DNA cleavage.

BACE INHIBITORS

The present invention provides BACE inhibitors of Formula (I): methods for their use and preparation, and intermediates for their preparation.

PEPTIDES HAVING RENIN INHIBITORY ACTIVITY, THEIR PREPARATION AND USE

Compounds of formula (I): STR1 [in which: R 1 is heterocyclic group having 5 or 6 ring atoms, or--NR 7 R 8, where R 7 is alkyl and R 8 is optionally substituted phenyl, optionally substituted phenylalkyl or cycloalkyl; R 2 is optionally substituted phenyl

RENIN INHIBIOTRS

Renin inhibiting compounds containing a single α-amino acid of the formula: STR1 and analogs thereof which inhibit the substrate-cleaving acting or renin, pharmaceutical compositions containing these compounds, processes for producing the compounds and methods of treating hypertension which employ the novel renin inhibitors.

Synthesis of Renin Inhibitors Containing a Sulfonemethylene Isostere at Their N-Terminals

We describe an efficient synthesis of highly active renin inhibitors containing a sulfonemethylene isostere at their N-terminals and a hydroxyethylene isosters at their C-terminals.The stereospecific synthesis of N-terminal key intermediate, L-N-norleucine t-butyl ester is described.

Asymmetric synthesis of 2-substituted-3-aminocarbonyl propionic acid.

An asymmetric synthetic route to 2-substituted-3-aminocarbonyl propionic acid, which is the significant component of low-molecular-weight renin inhibitors, is described. The key step of this synthesis is diastereoselective alkylation by using chiral oxazo

Renin inhibitors. Dipeptide analogues of angiotensinogen utilizing a structurally modified phenylalanine residue to impart proteolytic stability

A series of renin inhibitors have been prepared and evaluated for their susceptibility to cleavage by the serine protease chymotrypsin. The compounds were designed by consideration of the structural requirements in the active-site region of renin and chymotrypsin. By systematic alteration of the P3 phenylalanine residue, compounds with varying degrees of renin inhibitory potency and chymotrypsin susceptibility were obtained. Selected analogues from this group were examined in vivo for both their hypotensive effects and metabolic patterns.